CLOs on the Move

Envision Pharma Group

www.envisionpharmagroup.com

 
Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications, and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Critical Outcome Technologies

Critical Outcome Technologies Inc. is a London, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Michigan Technology and Research Institute

Michigan Technology & Research Institute, LLC is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Ivantis

Help control your eye pressure and possibly reduce your need for Glaucoma medication with the Hydrus® Microstent.

Hollister Stier

Hollister Stier is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TransCode Therapeutics

TransCode is an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company`s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. The Company believes that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. The Company`s other drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively. The Company is also developing diagnostic products related to its planned therapeutics business.